Onward and UPWARD.

Did you know seizures have been attributed to enzalutamide? We didn’t. The UPWARD prospective observational study of patients with at least one risk factor for seizure and receiving enzalutamide for metastatic castrate-resistant prostate cancer (mCRPC) demonstrated a similar seizure rate as that historically seen among mCRPC patients not receiving enzalutamide (2.6 versus 2.8 seizures, respectively, per 100 patient-years). So now you don’t have to worry about a problem you never knew you had.